Hela Cherif1, Saoussen Bacha1, Sonia Habibech1,
Hager Racil1, Sana Cheikhrouhou1, Naouel Chaouech1, Abdellatif Chabbou1
and Mohamed Lamine Megdiche1
Source : http://erj.ersjournals.com/content/48/suppl_60/PA4841
Medicine, Abderrahmane Mami Hospital, Ariana, Tunisia
Cytotoxic chemotherapy is widely used to palliate advanced
non-small-cell lung cancer (NSCLC) but can induce severe toxic events.
The aim of this study was to evaluate the chemotherapy toxicity in
adavanced non-small cell lung cancer (NSCLC) and its impact on overall
retrospectively reviewed 99 advanced stage NSCLC patients treated with
chemotherapy over a period of 3 years. Pre-therapeutic clinical and
biological data were assessed. OS was calculated using the Kaplan Meier
method and compared between two groups (having or not toxicity) by log
age was 65 years, 84% of patients had Performans status (PS) <2,
28% were malnourished (BMI <20 kg/m2). Anemia (Hb<12g/dL)
and hypoalbuminemia were observed respectively in 30% and 10% of cases.
Platinum chemotherapy regimen was used in 86% of cases. Seventy-eight
percent of the patients has developed at least one chemotherapy related
toxic event. Main toxicities were hematologic (47%; 26% of
toxicity≥ grade 3), gastrointestinal (30%; 58% of toxicity
≥ grade 3) and renal (20%; 9% of toxicity ≥ grade 3).
Eighty-five percent of toxic events occurred at the first line and on
average over 1.7 th cycle. No toxic death event has happened. Patients
with PS ≤2, anemia, malnutrition and hypoalbuminemia didn't
developed more chemotherapy-induced toxicity (p=0.66; p =0.48; p=0.93;
p=0.78 respectively). OS of patients with chemotherapy toxic event was
12.3 months compared with 7.51 months in patients without chemotherapy
toxic event (logrank; p = 0.002).
Our study suggested that Chemotherapy-induced toxicity in advanced
NSCLC patients was associated with poor survival.
Image : https://www.pancare.org.au/...